Skip to content

Effects of nalbuphine on postoperative analgesia after cesarean section under different background infusion methods

Effects of nalbuphine on postoperative analgesia after cesarean section under different background infusion methods

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062815
Enrollment
Unknown
Registered
2022-08-19
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after cesarean section

Interventions

normal background dose group:continous infusion rate 2 ml/h, single dose 2 ml
no background dose group:no continous infusion, single dose 4 ml
low background dose group:continous infusion rate 1 ml/h, single dose 3 ml

Sponsors

ZhongDa Hospital Southeast University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. The puerperae and their family members voluntarily use the electronic analgesia pump at their own expense and sign the informed consent form; 2. Single fetus and full-term pregnant women; 3. The blood coagulation function was normal: platelets 125-350x10^9/L, PT 9.4-12.5 s, APTT 25.1-36.5 s.

Exclusion criteria

Exclusion criteria: 1. Refuse to use electronic analgesia pump; 2. Have a history of local anesthetic allergy and opioid abuse; 3. Severe organic disease patients: (1) Cardiovascular disease: cardiac dysfunction, severe arrhythmia, acute coronary syndrome, hypertension crisis, aortic aneurysm or aortic dissection, acute pulmonary embolism; (2) Respiratory system disease: respiratory dysfunction, bronchiectasis with hemoptysis, status asthma; (3) Digestive system disease: liver cirrhosis decompensated, acute bleeding necrotizing pancreatitis, liver failure, acute suppurative obstructive cholangitis; (4) Renal dysfunction; (5) Nervous system diseases: severe cerebrovascular disease, intracranial organic disease, grand mal seizures, myasthenia gravis; (6) Severe endocrine and metabolic diseases combined with dysfunction of important organs; (7) Blood system diseases: aplastic anemia, severe anemia, leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, etc.; 4. Mental illness, communication disorder.

Design outcomes

Primary

MeasureTime frame
Pain scores;Cumulative dose of nalbuphine;Analgesic Remedy Situation;The occurrence of adverse reactions;

Secondary

MeasureTime frame
Number of sleep disturbances at night due to insufficient analgesia;first intestinal exhaust time after operation;the length of hospital stay;

Countries

China

Contacts

Public ContactHui Ye

ZhongDa Hospital Southeast University

carciapene@126.com+86 13675188113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026